HIV Infection, Immunodeficiency, Viral Replication, and the Risk of Cancer
Background: Few studies have compared cancer risk between HIV-infected individuals and a demographically similar HIV-uninfected internal comparison group, adjusting for cancer risk factors. Methods: We followed 20,775 HIV-infected and 215,158 HIV-uninfected individuals enrolled in Kaiser Permanente...
Saved in:
| Published in | Cancer epidemiology, biomarkers & prevention Vol. 20; no. 12; pp. 2551 - 2559 |
|---|---|
| Main Authors | , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Philadelphia, PA
American Association for Cancer Research
01.12.2011
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Background: Few studies have compared cancer risk between HIV-infected individuals and a demographically similar HIV-uninfected internal comparison group, adjusting for cancer risk factors.
Methods: We followed 20,775 HIV-infected and 215,158 HIV-uninfected individuals enrolled in Kaiser Permanente (KP) California for incident cancer from 1996 to 2008. Rate ratios (RR) were obtained from Poisson models comparing HIV-infected (overall and stratified by recent CD4 count and HIV RNA) with HIV-uninfected individuals, adjusted for age, sex, race/ethnicity, calendar period, KP region, smoking, alcohol/drug abuse, and overweight/obesity.
Results: We observed elevated RRs for Kaposi sarcoma (KS; RR = 199; P < 0.001), non-Hodgkin lymphoma (NHL; RR = 15; P < 0.001), anal cancer (RR = 55; P < 0.001), Hodgkin lymphoma (HL; RR = 19; P < 0.001), melanoma (RR = 1.8; P = 0.001), and liver cancer (RR = 1.8; P = 0.013), a reduced RR for prostate cancer (RR = 0.8; P = 0.012), and no increased risk for oral cavity/pharynx (RR = 1.4; P = 0.14), lung (RR = 1.2; P = 0.15), or colorectal (RR = 0.9; P = 0.34) cancers. Lung and oral cavity/pharynx cancers were elevated for HIV-infected subjects in models adjusted only for demographics. KS, NHL, anal cancer, HL, and colorectal cancer had significant (P < 0.05) trends for increasing RRs with decreasing recent CD4. The RRs for lung and oral cavity/pharynx cancer were significantly elevated with CD4 < 200 cells/μL and for melanoma and liver cancer with CD4 < 500 cells/μL. Only KS and NHL were associated with HIV RNA.
Conclusion: Immunodeficiency was positively associated with all cancers examined except prostate cancer among HIV-infected compared with HIV-uninfected individuals, after adjustment for several cancer risk factors.
Impact: Earlier antiretroviral therapy initiation to maintain high CD4 levels might reduce the burden of cancer in this population. Cancer Epidemiol Biomarkers Prev; 20(12); 2551–9. ©2011 AACR. |
|---|---|
| AbstractList | Background: Few studies have compared cancer risk between HIV-infected individuals and a demographically similar HIV-uninfected internal comparison group, adjusting for cancer risk factors.
Methods: We followed 20,775 HIV-infected and 215,158 HIV-uninfected individuals enrolled in Kaiser Permanente (KP) California for incident cancer from 1996 to 2008. Rate ratios (RR) were obtained from Poisson models comparing HIV-infected (overall and stratified by recent CD4 count and HIV RNA) with HIV-uninfected individuals, adjusted for age, sex, race/ethnicity, calendar period, KP region, smoking, alcohol/drug abuse, and overweight/obesity.
Results: We observed elevated RRs for Kaposi sarcoma (KS; RR = 199; P < 0.001), non-Hodgkin lymphoma (NHL; RR = 15; P < 0.001), anal cancer (RR = 55; P < 0.001), Hodgkin lymphoma (HL; RR = 19; P < 0.001), melanoma (RR = 1.8; P = 0.001), and liver cancer (RR = 1.8; P = 0.013), a reduced RR for prostate cancer (RR = 0.8; P = 0.012), and no increased risk for oral cavity/pharynx (RR = 1.4; P = 0.14), lung (RR = 1.2; P = 0.15), or colorectal (RR = 0.9; P = 0.34) cancers. Lung and oral cavity/pharynx cancers were elevated for HIV-infected subjects in models adjusted only for demographics. KS, NHL, anal cancer, HL, and colorectal cancer had significant (P < 0.05) trends for increasing RRs with decreasing recent CD4. The RRs for lung and oral cavity/pharynx cancer were significantly elevated with CD4 < 200 cells/μL and for melanoma and liver cancer with CD4 < 500 cells/μL. Only KS and NHL were associated with HIV RNA.
Conclusion: Immunodeficiency was positively associated with all cancers examined except prostate cancer among HIV-infected compared with HIV-uninfected individuals, after adjustment for several cancer risk factors.
Impact: Earlier antiretroviral therapy initiation to maintain high CD4 levels might reduce the burden of cancer in this population. Cancer Epidemiol Biomarkers Prev; 20(12); 2551–9. ©2011 AACR. BACKGROUND: Few studies have compared cancer risk between HIV-infected individuals and a demographically similar HIV-uninfected internal comparison group, adjusting for cancer risk factors. METHODS: We followed 20,775 HIV-infected and 215,158 HIV-uninfected individuals enrolled in Kaiser Permanente (KP) California for incident cancer from 1996 to 2008. Rate ratios (RR) were obtained from Poisson models comparing HIV-infected (overall and stratified by recent CD4 count and HIV RNA) with HIV-uninfected individuals, adjusted for age, sex, race/ethnicity, calendar period, KP region, smoking, alcohol/drug abuse, and overweight/obesity. RESULTS: We observed elevated RRs for Kaposi sarcoma (KS; RR = 199; P < 0.001), non-Hodgkin lymphoma (NHL; RR = 15; P < 0.001), anal cancer (RR = 55; P < 0.001), Hodgkin lymphoma (HL; RR = 19; P < 0.001), melanoma (RR = 1.8; P = 0.001), and liver cancer (RR = 1.8; P = 0.013), a reduced RR for prostate cancer (RR = 0.8; P = 0.012), and no increased risk for oral cavity/pharynx (RR = 1.4; P = 0.14), lung (RR = 1.2; P = 0.15), or colorectal (RR = 0.9; P = 0.34) cancers. Lung and oral cavity/pharynx cancers were elevated for HIV-infected subjects in models adjusted only for demographics. KS, NHL, anal cancer, HL, and colorectal cancer had significant (P < 0.05) trends for increasing RRs with decreasing recent CD4. The RRs for lung and oral cavity/pharynx cancer were significantly elevated with CD4 < 200 cells/ mu L and for melanoma and liver cancer with CD4 < 500 cells/ mu L. Only KS and NHL were associated with HIV RNA. CONCLUSION: Immunodeficiency was positively associated with all cancers examined except prostate cancer among HIV-infected compared with HIV-uninfected individuals, after adjustment for several cancer risk factors. IMPACT: Earlier antiretroviral therapy initiation to maintain high CD4 levels might reduce the burden of cancer in this population. Cancer Epidemiol Biomarkers Prev; 20(12); 2551-9. [copy ]2011 AACR. Few studies have compared cancer risk between HIV-infected individuals and a demographically similar HIV-uninfected internal comparison group, adjusting for cancer risk factors.BACKGROUNDFew studies have compared cancer risk between HIV-infected individuals and a demographically similar HIV-uninfected internal comparison group, adjusting for cancer risk factors.We followed 20,775 HIV-infected and 215,158 HIV-uninfected individuals enrolled in Kaiser Permanente (KP) California for incident cancer from 1996 to 2008. Rate ratios (RR) were obtained from Poisson models comparing HIV-infected (overall and stratified by recent CD4 count and HIV RNA) with HIV-uninfected individuals, adjusted for age, sex, race/ethnicity, calendar period, KP region, smoking, alcohol/drug abuse, and overweight/obesity.METHODSWe followed 20,775 HIV-infected and 215,158 HIV-uninfected individuals enrolled in Kaiser Permanente (KP) California for incident cancer from 1996 to 2008. Rate ratios (RR) were obtained from Poisson models comparing HIV-infected (overall and stratified by recent CD4 count and HIV RNA) with HIV-uninfected individuals, adjusted for age, sex, race/ethnicity, calendar period, KP region, smoking, alcohol/drug abuse, and overweight/obesity.We observed elevated RRs for Kaposi sarcoma (KS; RR = 199; P < 0.001), non-Hodgkin lymphoma (NHL; RR = 15; P < 0.001), anal cancer (RR = 55; P < 0.001), Hodgkin lymphoma (HL; RR = 19; P < 0.001), melanoma (RR = 1.8; P = 0.001), and liver cancer (RR = 1.8; P = 0.013), a reduced RR for prostate cancer (RR = 0.8; P = 0.012), and no increased risk for oral cavity/pharynx (RR = 1.4; P = 0.14), lung (RR = 1.2; P = 0.15), or colorectal (RR = 0.9; P = 0.34) cancers. Lung and oral cavity/pharynx cancers were elevated for HIV-infected subjects in models adjusted only for demographics. KS, NHL, anal cancer, HL, and colorectal cancer had significant (P < 0.05) trends for increasing RRs with decreasing recent CD4. The RRs for lung and oral cavity/pharynx cancer were significantly elevated with CD4 < 200 cells/μL and for melanoma and liver cancer with CD4 < 500 cells/μL. Only KS and NHL were associated with HIV RNA.RESULTSWe observed elevated RRs for Kaposi sarcoma (KS; RR = 199; P < 0.001), non-Hodgkin lymphoma (NHL; RR = 15; P < 0.001), anal cancer (RR = 55; P < 0.001), Hodgkin lymphoma (HL; RR = 19; P < 0.001), melanoma (RR = 1.8; P = 0.001), and liver cancer (RR = 1.8; P = 0.013), a reduced RR for prostate cancer (RR = 0.8; P = 0.012), and no increased risk for oral cavity/pharynx (RR = 1.4; P = 0.14), lung (RR = 1.2; P = 0.15), or colorectal (RR = 0.9; P = 0.34) cancers. Lung and oral cavity/pharynx cancers were elevated for HIV-infected subjects in models adjusted only for demographics. KS, NHL, anal cancer, HL, and colorectal cancer had significant (P < 0.05) trends for increasing RRs with decreasing recent CD4. The RRs for lung and oral cavity/pharynx cancer were significantly elevated with CD4 < 200 cells/μL and for melanoma and liver cancer with CD4 < 500 cells/μL. Only KS and NHL were associated with HIV RNA.Immunodeficiency was positively associated with all cancers examined except prostate cancer among HIV-infected compared with HIV-uninfected individuals, after adjustment for several cancer risk factors.CONCLUSIONImmunodeficiency was positively associated with all cancers examined except prostate cancer among HIV-infected compared with HIV-uninfected individuals, after adjustment for several cancer risk factors.Earlier antiretroviral therapy initiation to maintain high CD4 levels might reduce the burden of cancer in this population.IMPACTEarlier antiretroviral therapy initiation to maintain high CD4 levels might reduce the burden of cancer in this population. Few studies have compared cancer risk between HIV-infected individuals and a demographically similar HIV-uninfected internal comparison group, adjusting for cancer risk factors. We followed 20,775 HIV-infected and 215,158 HIV-uninfected individuals enrolled in Kaiser Permanente (KP) California for incident cancer from 1996 to 2008. Rate ratios (RR) were obtained from Poisson models comparing HIV-infected (overall and stratified by recent CD4 count and HIV RNA) with HIV-uninfected individuals, adjusted for age, sex, race/ethnicity, calendar period, KP region, smoking, alcohol/drug abuse, and overweight/obesity. We observed elevated RRs for Kaposi sarcoma (KS; RR = 199; P < 0.001), non-Hodgkin lymphoma (NHL; RR = 15; P < 0.001), anal cancer (RR = 55; P < 0.001), Hodgkin lymphoma (HL; RR = 19; P < 0.001), melanoma (RR = 1.8; P = 0.001), and liver cancer (RR = 1.8; P = 0.013), a reduced RR for prostate cancer (RR = 0.8; P = 0.012), and no increased risk for oral cavity/pharynx (RR = 1.4; P = 0.14), lung (RR = 1.2; P = 0.15), or colorectal (RR = 0.9; P = 0.34) cancers. Lung and oral cavity/pharynx cancers were elevated for HIV-infected subjects in models adjusted only for demographics. KS, NHL, anal cancer, HL, and colorectal cancer had significant (P < 0.05) trends for increasing RRs with decreasing recent CD4. The RRs for lung and oral cavity/pharynx cancer were significantly elevated with CD4 < 200 cells/μL and for melanoma and liver cancer with CD4 < 500 cells/μL. Only KS and NHL were associated with HIV RNA. Immunodeficiency was positively associated with all cancers examined except prostate cancer among HIV-infected compared with HIV-uninfected individuals, after adjustment for several cancer risk factors. Earlier antiretroviral therapy initiation to maintain high CD4 levels might reduce the burden of cancer in this population. |
| Author | Dubrow, Robert Horberg, Michael A. Quesenberry, Charles P. Towner, William J. Chao, Chun Xu, Lanfang Klein, Daniel Leyden, Wendy A. Neugebauer, Romain S. Abrams, Donald I. Silverberg, Michael J. |
| AuthorAffiliation | 2 Kaiser Permanente Southern California, Pasadena, CA, USA 1 Kaiser Permanente Northern California, Oakland, CA, USA 3 Mid-Atlantic Permanente Research Institute, Rockville, MD, USA 8 University of California San Francisco, San Francisco, CA, USA 5 Kaiser Permanente Southern California, Los Angeles, CA, USA 6 Yale School of Public Health and School of Medicine, New Haven, CT, USA 7 San Francisco General Hospital, San Francisco, CA, USA 4 Kaiser Permanente Northern California, Hayward, CA, USA |
| AuthorAffiliation_xml | – name: 4 Kaiser Permanente Northern California, Hayward, CA, USA – name: 3 Mid-Atlantic Permanente Research Institute, Rockville, MD, USA – name: 1 Kaiser Permanente Northern California, Oakland, CA, USA – name: 7 San Francisco General Hospital, San Francisco, CA, USA – name: 2 Kaiser Permanente Southern California, Pasadena, CA, USA – name: 5 Kaiser Permanente Southern California, Los Angeles, CA, USA – name: 6 Yale School of Public Health and School of Medicine, New Haven, CT, USA – name: 8 University of California San Francisco, San Francisco, CA, USA |
| Author_xml | – sequence: 1 givenname: Michael J. surname: Silverberg fullname: Silverberg, Michael J. – sequence: 2 givenname: Chun surname: Chao fullname: Chao, Chun – sequence: 3 givenname: Wendy A. surname: Leyden fullname: Leyden, Wendy A. – sequence: 4 givenname: Lanfang surname: Xu fullname: Xu, Lanfang – sequence: 5 givenname: Michael A. surname: Horberg fullname: Horberg, Michael A. – sequence: 6 givenname: Daniel surname: Klein fullname: Klein, Daniel – sequence: 7 givenname: William J. surname: Towner fullname: Towner, William J. – sequence: 8 givenname: Robert surname: Dubrow fullname: Dubrow, Robert – sequence: 9 givenname: Charles P. surname: Quesenberry fullname: Quesenberry, Charles P. – sequence: 10 givenname: Romain S. surname: Neugebauer fullname: Neugebauer, Romain S. – sequence: 11 givenname: Donald I. surname: Abrams fullname: Abrams, Donald I. |
| BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=25304703$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/22109347$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNkV9LHDEUxUNR6p_2I1TmpfjiaDKZu0koFGSxOiK0SOtryN5kanQm2U5mBb-92e6urT6UPiXc_O69J-fska0QgyPkA6PHjIE8YRSgVGoCx2ffmpKxkgoh3pBdBlyWQgBs5fuG2SF7Kd1RSoUCeEt2qopRxWuxSy4vmpuiCa3D0cdwVDR9vwjRutajdwEfj4obP5iuuHbzzqNZQSbYYrx1xbVP90Vsi6kJ6IZ3ZLs1XXLv1-c--fHl7Pv0orz6et5MT69KzNLG0kjBUXLEVkoEyqE2tTGcISpqRW0Zp3bGleAiVywaADljNpctzjidIN8nn1dz54tZ7yy6MGaFej743gyPOhqvX74Ef6t_xgfNKy5EBXnA4XrAEH8tXBp17xO6rjPBxUXSikkKtK7kf5BMcaYmKpMHf4t6VrNxOgMf14BJaLp2yJ759IcDTmtBeeY-rTgcYkqDazX68bfv-S--04zqZf56ma1eZqtz_rmkl_nnbnjVvVnw774nlWWy_w |
| CODEN | CEBPE4 |
| CitedBy_id | crossref_primary_10_1097_QCO_0000000000001076 crossref_primary_10_1097_QAI_0000000000001394 crossref_primary_10_1007_s00277_016_2588_z crossref_primary_10_7448_IAS_17_4_19856 crossref_primary_10_1093_ofid_ofad435 crossref_primary_10_1155_2019_6016278 crossref_primary_10_1097_QAD_0000000000000167 crossref_primary_10_1097_QAI_0000000000001719 crossref_primary_10_1080_17476348_2017_1288101 crossref_primary_10_1097_QAD_0000000000000283 crossref_primary_10_1016_j_drudis_2019_01_013 crossref_primary_10_7759_cureus_29428 crossref_primary_10_1093_cid_ciz329 crossref_primary_10_1002_cncr_27694 crossref_primary_10_1038_s41585_019_0194_2 crossref_primary_10_1001_jamanetworkopen_2020_7954 crossref_primary_10_1007_s11908_014_0424_y crossref_primary_10_1071_SH12070 crossref_primary_10_1007_s13277_014_2569_6 crossref_primary_10_1093_cid_ciw621 crossref_primary_10_1016_j_addbeh_2018_03_033 crossref_primary_10_1371_journal_ppat_1012063 crossref_primary_10_1371_journal_pone_0197665 crossref_primary_10_1097_SCS_0000000000003058 crossref_primary_10_1097_QAD_0000000000002003 crossref_primary_10_1097_QAI_0000000000001014 crossref_primary_10_1093_cid_cit369 crossref_primary_10_1177_2325957416682302 crossref_primary_10_1089_apc_2016_0165 crossref_primary_10_1111_resp_12249 crossref_primary_10_1186_s12981_023_00558_4 crossref_primary_10_1097_CCO_0b013e32836242b4 crossref_primary_10_1038_nrclinonc_2014_31 crossref_primary_10_1097_QAD_0000000000002933 crossref_primary_10_1016_j_bulcan_2018_02_002 crossref_primary_10_1111_apt_17654 crossref_primary_10_1016_j_mcna_2015_05_010 crossref_primary_10_1111_acer_14481 crossref_primary_10_1016_j_vaccine_2017_02_021 crossref_primary_10_2196_19081 crossref_primary_10_1177_0956462413499317 crossref_primary_10_7326_M14_2768 crossref_primary_10_1016_j_oraloncology_2014_09_011 crossref_primary_10_1093_cid_cit497 crossref_primary_10_1371_journal_pone_0085179 crossref_primary_10_1007_s11748_019_01149_9 crossref_primary_10_1093_annonc_mdv606 crossref_primary_10_1007_s00432_013_1477_2 crossref_primary_10_1177_0956462415586316 crossref_primary_10_1097_QAI_0000000000000146 crossref_primary_10_1097_QAD_0b013e32835c1333 crossref_primary_10_3390_idr13010017 crossref_primary_10_3390_jcm8020134 crossref_primary_10_3892_etm_2025_12816 crossref_primary_10_1016_j_oraloncology_2017_03_004 crossref_primary_10_3390_jcm10040716 crossref_primary_10_1111_bjh_12341 crossref_primary_10_1016_j_bulcan_2020_01_001 crossref_primary_10_1158_1055_9965_EPI_20_0281 crossref_primary_10_1002_cam4_5106 crossref_primary_10_1007_s00405_017_4672_y crossref_primary_10_1093_jnci_djx249 crossref_primary_10_1016_j_jaad_2014_05_046 crossref_primary_10_1093_infdis_jiv247 crossref_primary_10_1016_j_jcv_2015_11_037 crossref_primary_10_1016_S2352_3026_24_00210_2 crossref_primary_10_1016_j_ccm_2013_01_008 crossref_primary_10_1002_ijc_32730 crossref_primary_10_1007_s11908_014_0406_0 crossref_primary_10_1245_s10434_013_3353_3 crossref_primary_10_1053_j_seminoncol_2014_12_029 crossref_primary_10_1016_j_mmifmc_2024_01_004 crossref_primary_10_1002_cncr_32158 crossref_primary_10_1053_j_seminoncol_2014_12_027 crossref_primary_10_1038_s41391_020_00268_2 crossref_primary_10_1186_s13027_017_0144_7 crossref_primary_10_3390_cancers13225692 crossref_primary_10_1186_s13027_021_00413_z crossref_primary_10_1080_02791072_2016_1242180 crossref_primary_10_1097_COH_0000000000000063 crossref_primary_10_1007_s11904_014_0224_x crossref_primary_10_1371_journal_pone_0095096 crossref_primary_10_7448_IAS_17_4_19766 crossref_primary_10_1093_infdis_jiv277 crossref_primary_10_1097_01_aids_0000433236_55937_cb crossref_primary_10_1016_j_eimc_2013_04_001 crossref_primary_10_1097_OLQ_0000000000000745 crossref_primary_10_1093_ehjopen_oeab040 crossref_primary_10_1093_cid_ciab087 crossref_primary_10_1155_2013_946392 crossref_primary_10_1093_cid_ciw562 crossref_primary_10_3390_curroncol29030129 crossref_primary_10_3390_joma2010004 crossref_primary_10_1017_S0022215112000357 crossref_primary_10_1097_QAD_0000000000001773 crossref_primary_10_1186_s13027_019_0228_7 crossref_primary_10_1097_LGT_0000000000000117 crossref_primary_10_1097_QAI_0000000000001433 crossref_primary_10_1097_CCO_0b013e328363dfbd crossref_primary_10_1089_vim_2022_0177 crossref_primary_10_1089_aid_2020_0087 crossref_primary_10_1016_j_jiac_2016_10_002 crossref_primary_10_53730_ijhs_v1nS1_15233 crossref_primary_10_1200_GO_22_00262 crossref_primary_10_1016_j_vaccine_2012_06_045 crossref_primary_10_1093_cid_ciaa1046 crossref_primary_10_1136_bmjopen_2015_009778 crossref_primary_10_1053_j_gastro_2021_11_029 crossref_primary_10_1016_j_oraloncology_2017_12_014 crossref_primary_10_1007_s11904_012_0140_x crossref_primary_10_1097_QAD_0000000000000690 crossref_primary_10_1016_S2352_3018_16_30215_6 crossref_primary_10_7124_bc_00005B crossref_primary_10_1093_cid_civ012 crossref_primary_10_1158_1055_9965_EPI_14_1079 crossref_primary_10_1016_S2352_3018_22_00368_X crossref_primary_10_1089_vim_2013_0130 crossref_primary_10_1016_j_hpb_2025_01_001 crossref_primary_10_1097_QAI_0000000000000202 crossref_primary_10_1200_JCO_2012_44_5486 crossref_primary_10_1002_jmv_24441 crossref_primary_10_1097_QAD_0000000000001434 crossref_primary_10_1080_09540121_2013_855700 crossref_primary_10_1097_QAD_0000000000001433 crossref_primary_10_1111_hiv_12098 crossref_primary_10_1080_15284336_2018_1523826 crossref_primary_10_1016_j_idc_2017_07_007 crossref_primary_10_1155_2016_2138259 crossref_primary_10_1093_jac_dkt206 crossref_primary_10_1097_CCO_0b013e328363dfdb crossref_primary_10_3109_00365548_2012_737476 crossref_primary_10_1007_s10461_019_02742_y crossref_primary_10_1016_j_canep_2016_09_007 crossref_primary_10_1007_s11904_013_0166_8 crossref_primary_10_1007_s10552_017_0896_9 crossref_primary_10_1002_pds_5256 crossref_primary_10_1097_QAD_0000000000002654 crossref_primary_10_1097_QAD_0000000000000352 crossref_primary_10_1097_QAD_0000000000003740 crossref_primary_10_1097_COH_0000000000000025 crossref_primary_10_1097_OLQ_0000000000000145 crossref_primary_10_1186_s13027_021_00365_4 crossref_primary_10_1097_QAI_0000000000002040 crossref_primary_10_1093_cid_ciu869 crossref_primary_10_1016_j_bulcan_2018_11_003 crossref_primary_10_1016_j_oooo_2020_11_007 crossref_primary_10_1007_s11904_014_0254_4 crossref_primary_10_1097_QAD_0b013e32835935b3 crossref_primary_10_1097_AOG_0000000000002371 crossref_primary_10_1182_blood_2012_02_387092 crossref_primary_10_1177_0956462415615764 crossref_primary_10_9778_cmajo_20220230 crossref_primary_10_1111_odi_12365 crossref_primary_10_1097_QAD_0000000000001451 crossref_primary_10_1007_s11908_018_0626_9 crossref_primary_10_1097_CCO_0b013e328355e131 crossref_primary_10_1093_cid_ciu076 crossref_primary_10_1093_infdis_jiaa786 crossref_primary_10_3390_cells13151246 crossref_primary_10_1093_cid_ciz762 crossref_primary_10_1097_QAD_0000000000001588 crossref_primary_10_1007_s11904_016_0313_0 crossref_primary_10_1111_hiv_12546 crossref_primary_10_1097_COH_0000000000000330 crossref_primary_10_1093_cid_ciae652 crossref_primary_10_1097_QAI_0000000000003350 crossref_primary_10_2169_internalmedicine_52_0523 crossref_primary_10_1097_CCO_0b013e32835793f1 crossref_primary_10_1097_QAI_0000000000000083 crossref_primary_10_1093_jnci_djs529 crossref_primary_10_1007_s11065_021_09527_y crossref_primary_10_1016_S2352_3018_18_30360_6 crossref_primary_10_1097_QAI_0b013e3182968fa7 crossref_primary_10_1089_apc_2015_0040 crossref_primary_10_22625_2072_6732_2018_10_3_61_69 crossref_primary_10_1097_QAI_0000000000000881 crossref_primary_10_1016_j_amjoto_2021_103234 crossref_primary_10_1097_QAI_0000000000002024 crossref_primary_10_1016_j_clindermatol_2023_12_006 crossref_primary_10_1089_aid_2014_0279 crossref_primary_10_1097_QAD_0000000000000382 crossref_primary_10_1089_aid_2019_0064 crossref_primary_10_1097_COH_0000000000000334 crossref_primary_10_1053_j_seminoncol_2015_09_011 crossref_primary_10_1097_QAD_0b013e32835f6b0c crossref_primary_10_1186_s13256_021_02920_4 crossref_primary_10_1007_s11904_015_0283_7 crossref_primary_10_1200_JCO_2016_67_6999 crossref_primary_10_1097_QAD_0000000000002218 crossref_primary_10_1097_QAD_0b013e328352d1ad crossref_primary_10_1097_LGT_0000000000000864 crossref_primary_10_1684_bdc_2014_2025 crossref_primary_10_1097_QAI_0000000000002930 |
| Cites_doi | 10.1093/cid/cir207 10.1086/605890 10.1182/blood-2009-02-204172 10.1371/journal.pmed.0050203 10.1097/QAI.0b013e3181b327ca 10.1177/135965350801300301 10.1158/1055-9965.EPI-10-0741 10.1016/S1470-2045(09)70282-7 10.1159/000386035 10.1097/QAD.0b013e3282f2705d 10.1097/00126334-200408010-00013 10.1016/S0140-6736(09)60612-7 10.1097/QAI.0b013e3181b033ab 10.1093/jnci/dji072 10.1200/JCO.2006.05.7984 10.1093/jnci/djp205 10.1182/blood-2006-05-024109 10.1002/ijc.1528 10.7326/0003-4819-148-10-200805200-00005 10.1097/QAD.0b013e3283112b77 10.1093/jnci/91.3.226 10.1016/j.jhep.2004.05.001 10.1097/QAI.0b013e3181f53783 10.1056/NEJMoa0807252 10.1056/NEJM199804023381403 10.1086/518606 10.1097/QAD.0b013e328317cc2d 10.1086/651688 10.1097/01.aids.0000238411.75324.59 10.1002/ijc.23487 10.1016/S0140-6736(07)61050-2 10.1002/cncr.21334 10.1097/QAD.0b013e3280118fca 10.1016/j.ejim.2004.09.011 10.1086/652749 10.1038/sj.bjc.6604520 10.1097/QAI.0b013e3181eef4f7 10.1002/cncr.25311 10.2217/fon.09.28 10.1086/605594 10.1097/QAD.0b013e3283319184 10.1097/QAD.0b013e32831103ad 10.7326/0003-4819-154-8-201104190-00001 10.1159/000328032 10.1200/JCO.2005.03.4413 10.1086/376509 |
| ContentType | Journal Article |
| Copyright | 2015 INIST-CNRS |
| Copyright_xml | – notice: 2015 INIST-CNRS |
| DBID | AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7X8 7T2 7T5 7U1 7U9 C1K H94 5PM |
| DOI | 10.1158/1055-9965.EPI-11-0777 |
| DatabaseName | CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic Health and Safety Science Abstracts (Full archive) Immunology Abstracts Risk Abstracts Virology and AIDS Abstracts Environmental Sciences and Pollution Management AIDS and Cancer Research Abstracts PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic Risk Abstracts AIDS and Cancer Research Abstracts Health & Safety Science Abstracts Immunology Abstracts Virology and AIDS Abstracts Environmental Sciences and Pollution Management |
| DatabaseTitleList | CrossRef Risk Abstracts MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1538-7755 |
| EndPage | 2559 |
| ExternalDocumentID | PMC3237725 22109347 25304703 10_1158_1055_9965_EPI_11_0777 |
| Genre | Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
| GeographicLocations | USA, California |
| GeographicLocations_xml | – name: USA, California |
| GrantInformation_xml | – fundername: NIAID NIH HHS grantid: K01 AI071725 – fundername: NIAAA NIH HHS grantid: U10-AA13566 – fundername: NIAAA NIH HHS grantid: U10 AA013566 – fundername: NIAID NIH HHS grantid: K01AI071725 – fundername: National Institute of Allergy and Infectious Diseases Extramural Activities : NIAID grantid: K01 AI071725-05 || AI – fundername: National Institute on Alcohol Abuse and Alcoholism : NIAAA grantid: U10 AA013566-10 || AA |
| GroupedDBID | --- 18M 29B 2FS 2WC 34G 39C 53G 5GY 5VS 6J9 AAFWJ AAYXX ABOCM ACPRK ADBBV ADCOW AENEX AFHIN AFRAH ALMA_UNASSIGNED_HOLDINGS BR6 BTFSW C1A CITATION CS3 DIK DU5 E3Z EBS EJD F5P FRP H13 IH2 KQ8 L7B OK1 P2P PQQKQ QTD RCR RHI SJN UDS W8F WOQ .55 3O- AI. H~9 IQODW VH1 WHG X7M ZXP CGR CUY CVF ECM EIF NPM 7X8 7T2 7T5 7U1 7U9 C1K H94 5PM |
| ID | FETCH-LOGICAL-c538t-a873c83ccf88c50354a4aa31cc90d74d130db39737cc9dca558b1dd13dcb306c3 |
| ISSN | 1055-9965 1538-7755 |
| IngestDate | Thu Aug 21 18:20:13 EDT 2025 Fri Jul 11 00:29:25 EDT 2025 Fri Jul 11 15:45:07 EDT 2025 Mon Jul 21 06:07:29 EDT 2025 Mon Jul 21 09:13:22 EDT 2025 Tue Jul 01 04:31:23 EDT 2025 Thu Apr 24 23:00:25 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 12 |
| Keywords | Infection Immunopathology Cancerology Viral disease Risk factor Risk Replication AIDS Malignant tumor Immune deficiency Cancer |
| Language | English |
| License | CC BY 4.0 |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c538t-a873c83ccf88c50354a4aa31cc90d74d130db39737cc9dca558b1dd13dcb306c3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Article-2 ObjectType-Feature-1 |
| OpenAccessLink | https://aacrjournals.org/cebp/article-pdf/20/12/2551/2272615/2551.pdf |
| PMID | 22109347 |
| PQID | 911931969 |
| PQPubID | 23479 |
| PageCount | 9 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_3237725 proquest_miscellaneous_918050428 proquest_miscellaneous_911931969 pubmed_primary_22109347 pascalfrancis_primary_25304703 crossref_citationtrail_10_1158_1055_9965_EPI_11_0777 crossref_primary_10_1158_1055_9965_EPI_11_0777 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2011-12-01 |
| PublicationDateYYYYMMDD | 2011-12-01 |
| PublicationDate_xml | – month: 12 year: 2011 text: 2011-12-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | Philadelphia, PA |
| PublicationPlace_xml | – name: Philadelphia, PA – name: United States |
| PublicationTitle | Cancer epidemiology, biomarkers & prevention |
| PublicationTitleAlternate | Cancer Epidemiol Biomarkers Prev |
| PublicationYear | 2011 |
| Publisher | American Association for Cancer Research |
| Publisher_xml | – name: American Association for Cancer Research |
| References | Patel (2022060919553625800_bib3) 2008; 148 Guiguet (2022060919553625800_bib16) 2009; 10 Shiels (2022060919553625800_bib26) 2010; 55 Polesel (2022060919553625800_bib29) 2008; 22 Biggar (2022060919553625800_bib33) 2006; 108 Rauch (2022060919553625800_bib38) 2008; 13 Chaturvedi (2022060919553625800_bib1) 2009; 101 Vallet-Pichard (2022060919553625800_bib13) 2004; 41 Clifford (2022060919553625800_bib34) 2008; 22 Crum-Cianflone (2022060919553625800_bib37) 2009; 23 French (2022060919553625800_bib41) 2009; 200 Sterne (2022060919553625800_bib48) 2009; 373 Engels (2022060919553625800_bib25) 2006; 24 Neuhaus (2022060919553625800_bib43) 2010; 201 Martin (2022060919553625800_bib11) 1998; 338 Chaturvedi (2022060919553625800_bib24) 2007; 21 Engels (2022060919553625800_bib20) 2006; 20 Shiels (2022060919553625800_bib2) 2009; 52 Bruyand (2022060919553625800_bib30) 2009; 49 Krishnan (2022060919553625800_bib32) 2011; 80 Gordon (2022060919553625800_bib19) 2006 Clifford (2022060919553625800_bib27) 2009; 5 Engels (2022060919553625800_bib4) 2008; 123 Grulich (2022060919553625800_bib21) 2007; 370 Shiels (2022060919553625800_bib22) 2010; 19 Franceschi (2022060919553625800_bib28) 2008; 99 Shebl (2022060919553625800_bib40) 2010; 55 Clifford (2022060919553625800_bib36) 2009; 113 Phelps (2022060919553625800_bib8) 2001; 94 Silverberg (2022060919553625800_bib5) 2009; 23 Burnet (2022060919553625800_bib39) 1970; 13 Kitahata (2022060919553625800_bib47) 2009; 360 Kuller (2022060919553625800_bib42) 2008; 5 Palefsky (2022060919553625800_bib12) 1999; 91 Reekie (2022060919553625800_bib14) 2010; 116 Kesselring (2022060919553625800_bib15) 2011; 52 McGinnis (2022060919553625800_bib18) 2006; 24 Landay (2022060919553625800_bib44) 2003; 188 Bedimo (2022060919553625800_bib17) 2009; 52 Clifford (2022060919553625800_bib6) 2005; 97 Evans (2022060919553625800_bib10) 2006 Monforte (2022060919553625800_bib45) 2008; 22 Hessol (2022060919553625800_bib7) 2004; 36 Kirk (2022060919553625800_bib23) 2007; 45 Burgi (2022060919553625800_bib35) 2005; 104 Murillas (2022060919553625800_bib9) 2005; 16 HIV-CAUSAL Collaboration (2022060919553625800_bib46) 2011; 154 Prosperi (2022060919553625800_bib31); 50 |
| References_xml | – volume: 52 start-page: 1458 year: 2011 ident: 2022060919553625800_bib15 article-title: Immunodeficiency as a Risk Factor for Non-AIDS-Defining Malignancies in HIV-1-Infected Patients Receiving Combination Antiretroviral Therapy publication-title: Clin Infect Dis doi: 10.1093/cid/cir207 – volume: 200 start-page: 1212 year: 2009 ident: 2022060919553625800_bib41 article-title: Serum immune activation markers are persistently increased in patients with HIV infection after 6 years of antiretroviral therapy despite suppression of viral replication and reconstitution of CD4+ T cells publication-title: J Infect Dis doi: 10.1086/605890 – volume: 113 start-page: 5737 year: 2009 ident: 2022060919553625800_bib36 article-title: Hodgkin lymphoma in the Swiss HIV Cohort Study publication-title: Blood doi: 10.1182/blood-2009-02-204172 – volume: 5 start-page: e203 year: 2008 ident: 2022060919553625800_bib42 article-title: Inflammatory and coagulation biomarkers and mortality in patients with HIV infection publication-title: PLoS Med doi: 10.1371/journal.pmed.0050203 – volume: 52 start-page: 611 year: 2009 ident: 2022060919553625800_bib2 article-title: A meta-analysis of the incidence of non-AIDS cancers in HIV-infected individuals publication-title: J Acquir Immune Defic Syndr doi: 10.1097/QAI.0b013e3181b327ca – volume: 13 start-page: 455 year: 2008 ident: 2022060919553625800_bib38 article-title: Low current and nadir CD4+ T-cell counts are associated with higher hepatitis C virus RNA levels in the Swiss HIV cohort study publication-title: Antivir Ther doi: 10.1177/135965350801300301 – volume: 19 start-page: 2910 year: 2010 ident: 2022060919553625800_bib22 article-title: Reduced risk of prostate cancer in U.S. men with AIDS publication-title: Cancer Epidemiol Biomarkers Prev doi: 10.1158/1055-9965.EPI-10-0741 – volume: 10 start-page: 1152 year: 2009 ident: 2022060919553625800_bib16 article-title: Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study publication-title: Lancet Oncol doi: 10.1016/S1470-2045(09)70282-7 – volume: 13 start-page: 1 year: 1970 ident: 2022060919553625800_bib39 article-title: The concept of immunological surveillance publication-title: Prog Exp Tumor Res doi: 10.1159/000386035 – volume: 22 start-page: 301 year: 2008 ident: 2022060919553625800_bib29 article-title: Non-Hodgkin lymphoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy publication-title: AIDS doi: 10.1097/QAD.0b013e3282f2705d – volume: 36 start-page: 978 year: 2004 ident: 2022060919553625800_bib7 article-title: Cancer risk among participants in the Women's Interagency HIV Study publication-title: J Acquir Immune Defic Syndr doi: 10.1097/00126334-200408010-00013 – volume: 373 start-page: 1352 year: 2009 ident: 2022060919553625800_bib48 article-title: Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies publication-title: Lancet doi: 10.1016/S0140-6736(09)60612-7 – volume: 52 start-page: 203 year: 2009 ident: 2022060919553625800_bib17 article-title: Incidence of non-AIDS-defining malignancies in HIV-infected versus noninfected patients in the HAART Era: impact of immunosuppression publication-title: J Acquir Immune Defic Syndr doi: 10.1097/QAI.0b013e3181b033ab – volume: 97 start-page: 425 year: 2005 ident: 2022060919553625800_bib6 article-title: Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy publication-title: J Natl Cancer Inst doi: 10.1093/jnci/dji072 – volume: 24 start-page: 5005 year: 2006 ident: 2022060919553625800_bib18 article-title: Hepatocellular carcinoma and non-Hodgkin's lymphoma: the roles of HIV, hepatitis C infection, and alcohol abuse publication-title: J Clin Oncol doi: 10.1200/JCO.2006.05.7984 – volume: 101 start-page: 1120 year: 2009 ident: 2022060919553625800_bib1 article-title: Risk of human papillomavirus-associated cancers among persons with AIDS publication-title: J Natl Cancer Inst doi: 10.1093/jnci/djp205 – volume: 108 start-page: 3786 year: 2006 ident: 2022060919553625800_bib33 article-title: Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDS publication-title: Blood doi: 10.1182/blood-2006-05-024109 – volume: 94 start-page: 753 year: 2001 ident: 2022060919553625800_bib8 article-title: Cancer incidence in women with or at risk for HIV publication-title: Int J Cancer doi: 10.1002/ijc.1528 – volume: 148 start-page: 728 year: 2008 ident: 2022060919553625800_bib3 article-title: Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992–2003 publication-title: Ann Intern Med doi: 10.7326/0003-4819-148-10-200805200-00005 – volume: 22 start-page: 2143 year: 2008 ident: 2022060919553625800_bib45 article-title: HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies publication-title: AIDS doi: 10.1097/QAD.0b013e3283112b77 – volume: 91 start-page: 226 year: 1999 ident: 2022060919553625800_bib12 article-title: Cervicovaginal human papillomavirus infection in human immunodeficiency virus-1 (HIV)-positive and high-risk HIV-negative women publication-title: J Natl Cancer Inst doi: 10.1093/jnci/91.3.226 – volume: 41 start-page: 156 year: 2004 ident: 2022060919553625800_bib13 article-title: Hepatitis viruses and human immunodeficiency virus co-infection: pathogenesis and treatment publication-title: J Hepatol doi: 10.1016/j.jhep.2004.05.001 – volume: 55 start-page: 510 year: 2010 ident: 2022060919553625800_bib26 article-title: Lung cancer incidence and mortality among HIV-infected and HIV-uninfected injection drug users publication-title: J Acquir Immune Defic Syndr doi: 10.1097/QAI.0b013e3181f53783 – volume: 360 start-page: 1815 year: 2009 ident: 2022060919553625800_bib47 article-title: Effect of early versus deferred antiretroviral therapy for HIV on survival publication-title: N Engl J Med doi: 10.1056/NEJMoa0807252 – volume: 338 start-page: 948 year: 1998 ident: 2022060919553625800_bib11 article-title: Sexual transmission and the natural history of human herpesvirus 8 infection publication-title: N Engl J Med doi: 10.1056/NEJM199804023381403 – year: 2006 ident: 2022060919553625800_bib10 article-title: Viral infections of humans: epidemiology and control – volume: 45 start-page: 103 year: 2007 ident: 2022060919553625800_bib23 article-title: HIV infection is associated with an increased risk for lung cancer, independent of smoking publication-title: Clin Infect Dis doi: 10.1086/518606 – volume: 23 start-page: 41 year: 2009 ident: 2022060919553625800_bib37 article-title: Trends in the incidence of cancers among HIV-infected persons and the impact of antiretroviral therapy: a 20-year cohort study publication-title: AIDS doi: 10.1097/QAD.0b013e328317cc2d – volume: 50 start-page: 1316 ident: 2022060919553625800_bib31 article-title: Incidence of malignancies in HIV-infected patients and prognostic role of current CD4 cell count: evidence from a large Italian cohort study publication-title: Clin Infect Dis doi: 10.1086/651688 – volume: 20 start-page: 1645 year: 2006 ident: 2022060919553625800_bib20 article-title: Trends in cancer risk among people with AIDS in the United States 1980–2002 publication-title: AIDS doi: 10.1097/01.aids.0000238411.75324.59 – volume: 123 start-page: 187 year: 2008 ident: 2022060919553625800_bib4 article-title: Cancer risk in people infected with human immunodeficiency virus in the United States publication-title: Int J Cancer doi: 10.1002/ijc.23487 – volume: 370 start-page: 59 year: 2007 ident: 2022060919553625800_bib21 article-title: Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis publication-title: Lancet doi: 10.1016/S0140-6736(07)61050-2 – volume: 104 start-page: 1505 year: 2005 ident: 2022060919553625800_bib35 article-title: Incidence and risk factors for the occurrence of non-AIDS-defining cancers among human immunodeficiency virus-infected individuals publication-title: Cancer doi: 10.1002/cncr.21334 – volume: 21 start-page: 207 year: 2007 ident: 2022060919553625800_bib24 article-title: Elevated risk of lung cancer among people with AIDS publication-title: AIDS doi: 10.1097/QAD.0b013e3280118fca – volume: 16 start-page: 113 year: 2005 ident: 2022060919553625800_bib9 article-title: Increased incidence of hepatocellular carcinoma (HCC) in HIV-1 infected patients publication-title: Eur J Intern Med doi: 10.1016/j.ejim.2004.09.011 – year: 2006 ident: 2022060919553625800_bib19 article-title: How does the adult Kaiser Permanente Membership in Northern California compare with the larger community? – volume: 201 start-page: 1788 year: 2010 ident: 2022060919553625800_bib43 article-title: Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection publication-title: J Infect Dis doi: 10.1086/652749 – volume: 99 start-page: 800 year: 2008 ident: 2022060919553625800_bib28 article-title: Kaposi sarcoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy publication-title: Br J Cancer doi: 10.1038/sj.bjc.6604520 – volume: 55 start-page: 375 year: 2010 ident: 2022060919553625800_bib40 article-title: Pulmonary infections and risk of lung cancer among persons with AIDS publication-title: J Acquir Immune Defic Syndr doi: 10.1097/QAI.0b013e3181eef4f7 – volume: 116 start-page: 5306 year: 2010 ident: 2022060919553625800_bib14 article-title: Relationship between current level of immunodeficiency and non-acquired immunodeficiency syndrome-defining malignancies publication-title: Cancer doi: 10.1002/cncr.25311 – volume: 5 start-page: 669 year: 2009 ident: 2022060919553625800_bib27 article-title: Cancer risk in HIV-infected persons: influence of CD4(+) count publication-title: Future Oncol doi: 10.2217/fon.09.28 – volume: 49 start-page: 1109 year: 2009 ident: 2022060919553625800_bib30 article-title: Role of uncontrolled HIV RNA level and immunodeficiency in the occurrence of malignancy in HIV-infected patients during the combination antiretroviral therapy era: Agence Nationale de Recherche sur le Sida (ANRS) CO3 Aquitaine Cohort publication-title: Clin Infect Dis doi: 10.1086/605594 – volume: 23 start-page: 2337 year: 2009 ident: 2022060919553625800_bib5 article-title: HIV infection and the risk of cancers with and without a known infectious cause publication-title: AIDS doi: 10.1097/QAD.0b013e3283319184 – volume: 22 start-page: 2135 year: 2008 ident: 2022060919553625800_bib34 article-title: Influence of HIV-related immunodeficiency on the risk of hepatocellular carcinoma publication-title: AIDS doi: 10.1097/QAD.0b013e32831103ad – volume: 154 start-page: 509 year: 2011 ident: 2022060919553625800_bib46 article-title: When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining Illness in HIV-infected persons in developed countries: an observational study publication-title: Ann Intern Med doi: 10.7326/0003-4819-154-8-201104190-00001 – volume: 80 start-page: 42 year: 2011 ident: 2022060919553625800_bib32 article-title: Incidence of non-AIDS-defining cancer in antiretroviral treatment-naive subjects after antiretroviral treatment initiation: An ACTG Longitudinal Linked Randomized Trials Analysis publication-title: Oncology doi: 10.1159/000328032 – volume: 24 start-page: 1383 year: 2006 ident: 2022060919553625800_bib25 article-title: Elevated incidence of lung cancer among HIV-infected individuals publication-title: J Clin Oncol doi: 10.1200/JCO.2005.03.4413 – volume: 188 start-page: 209 year: 2003 ident: 2022060919553625800_bib44 article-title: Correlates of immune activation marker changes in human immunodeficiency virus (HIV)-seropositive and high-risk HIV-seronegative women who use illicit drugs publication-title: J Infect Dis doi: 10.1086/376509 |
| SSID | ssj0007955 |
| Score | 2.48085 |
| Snippet | Background: Few studies have compared cancer risk between HIV-infected individuals and a demographically similar HIV-uninfected internal comparison group,... Few studies have compared cancer risk between HIV-infected individuals and a demographically similar HIV-uninfected internal comparison group, adjusting for... BACKGROUND: Few studies have compared cancer risk between HIV-infected individuals and a demographically similar HIV-uninfected internal comparison group,... |
| SourceID | pubmedcentral proquest pubmed pascalfrancis crossref |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 2551 |
| SubjectTerms | Adult Anti-HIV Agents - administration & dosage Biological and medical sciences Cohort Studies Female HIV Infections - drug therapy HIV Infections - immunology HIV Infections - virology Human viral diseases Humans Infectious diseases Male Medical sciences Neoplasms - immunology Neoplasms - virology Risk Factors Tumors Viral diseases Viral diseases of the lymphoid tissue and the blood. Aids Viral Load Virus Replication |
| Title | HIV Infection, Immunodeficiency, Viral Replication, and the Risk of Cancer |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/22109347 https://www.proquest.com/docview/911931969 https://www.proquest.com/docview/918050428 https://pubmed.ncbi.nlm.nih.gov/PMC3237725 |
| Volume | 20 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwELeqISEkhPhe-Zj8wNuakTpxkzx2XaEddKBug71Fju2ISiit-vEA_xX_IXeO46RVxYCXqHVjJ_X9bN_Zv7sj5E3c9XXWS7THQV_wQiZgSAkwVliW571QMyZM1pLJRW90HZ7f8JtW61eDtbRZZyfy516_kv-RKpSBXNFL9h8k6xqFAvgM8oUrSBiufyXjEdhuY8umKj240NtjrjSGhUCfSsNinS1NAH13UF0RNlHlnFpm-QCFv2xqqmXJsa4zyJrW0F0fGT3LlQHNwkaAqg_zL8cfvwynp8Pp-wYrvz58GoyuL44Ho_4nh7TTaX9yWeryuE1db-OC6nw2NCyEr7pQP-yuq3Jbrjtsj-roqQE4w6G0f6SiGDZmYZ9zDwwx3pymmd-EI2tOutzGrNXV12T_4sBjs09hG4fbZ8arMLKJZLaCce8sko66yDgeVGJ82TsMLBNMmnE2_uAW_ygxiXbdQ6zTGDz67d4Hb6lD9xdiBSMzL1Oq7LN5dqm7DV3o6iF5YI0Y2i8R-Yi0dPGY3J1YmsYTcg7ApA6YHboLyw41oKQNUHYoQJICJClCks5zWsrtKbl-N7wajDybtMOTsHauPRFHgYwDKfM4ltwPeChCIYKulImvolCBzqQyUIKDCEqUFJzHWVdBsZIZmK8yeEYOinmhDwnNGFiz3QxWDRGFTPoZaN9SJToUea5yptokrPoulTaiPSZW-Z4ay5bHKXZ5il2eDj-PoSjFLm-TE1dtUYZ0ua3C0ZZgXK0KC21CK0mlMDvjkZso9HyzSkGVSHCRS_50S-xz3Llok-elbOv2GQZ7C-EFoi2puxswNvz2L8Xsm4kRH7AA0Mlf3PbqL8m9esi-Igfr5Ua_BjV7nR0ZYP8Gsz3N6g |
| linkProvider | Flying Publisher |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=HIV+Infection%2C+Immunodeficiency%2C+Viral+Replication%2C+and+the+Risk+of+Cancer&rft.jtitle=Cancer+epidemiology%2C+biomarkers+%26+prevention&rft.au=SILVERBERG%2C+Michael+J&rft.au=CHUN+CHAO&rft.au=ABRAMS%2C+Donald+I&rft.au=LEYDEN%2C+Wendy+A&rft.date=2011-12-01&rft.pub=American+Association+for+Cancer+Research&rft.issn=1055-9965&rft.volume=20&rft.issue=12&rft.spage=2551&rft.epage=2559&rft_id=info:doi/10.1158%2F1055-9965.epi-11-0777&rft.externalDBID=n%2Fa&rft.externalDocID=25304703 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1055-9965&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1055-9965&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1055-9965&client=summon |